论文部分内容阅读
许多人类血管源性眼病均与血管内皮生长因子(VEGF)有关。近年来玻璃体腔注射抗VEGF药物治疗血管源性眼病逐渐应用于临床,就macugen,lucentis和avastin三种抗VEGF药物的基础研究、临床应用进展及不良反应情况进行综述,从生物学特性、临床疗效及应用前景等方面分析比较三种药物的共同点与特异性。
Many human vasogenic eye diseases are associated with vascular endothelial growth factor (VEGF). In recent years, intravitreal injection of anti-VEGF drugs for the treatment of vasogenic eye disease gradually applied to clinical, macugen, lucentis and avastin three anti-VEGF drugs basic research, clinical application and adverse reactions were reviewed, from the biological characteristics, clinical efficacy And application prospects analysis and comparison of three drugs in common and specificity.